



NEONATAL Medication Monograph



# GLYCOPYRROLATE (Glycopyrronium)

This document should be read in conjunction with this [DISCLAIMER](#)

**Highly Restricted:** Requires Neonatologist or Respiratory Physician approval before commencing

<b>Presentation</b>	<b>Vial:</b> 200 microgram/mL (suitable for ORAL use) <b>Oral solution:</b> 200microgram /mL
<b>Description</b>	Antimuscarinic agent with atropine-like actions
<b>Indications</b>	Used to reduce excessive respiratory tract secretions.
<b>Precautions</b>	Medical conditions that preclude the use of anticholinergics
<b>Dosage</b>	<i>There is limited information regarding the use of glycopyrollate in neonates – consult neonatologist prior to initiating</i>  <b><u>IV/IM:</u></b> 4– 9microgram/ kg/ dose every 6 to 8 hours <b>Maximum:</b> 200mcirograms <b><u>Oral:</u></b> 40-100microgram/ kg/ dose 3 to 4 times daily  Dose adjusted according to response
<b>Dosage Adjustment</b>	May be required in renal impairment due to reduced administration
<b>Adverse Reactions</b>	<b>Common:</b> Drowsiness, insomnia, tachycardia, urinary retention, constipation, inhibition of sweating.
	<b>Serious:</b> Arrhythmia, malignant hyperthermia
<b>Compatible Fluids</b>	Sodium Chloride 0.9%, Glucose 5%, Glucose 10%
<b>Preparation</b>	Can be diluted to aid administration of small doses Withdraw 1mL of 200microgram/mL solution and add to 4mL of a compatible fluid. Concentration = 200microgram/5mL <u>Final concentration = 40microgram/mL</u>

<b>Administration</b>	<p><b>Oral:</b> May be given at any time with regard to feeds.</p> <p><b>IV:</b> Inject over 3-4 minutes</p> <p><b>IM:</b> as per NCCU protocol</p>
<b>Monitoring</b>	Monitor heart rate, bowel sounds and movements
<b>Storage</b>	Store at room temperature, below 25°C
<b>Notes</b>	<b>Antidote:</b> Neostigmine
<b>References</b>	<p>British National Formulary. BNF for Children. 2018-19 ed. London, UK: BMJ Group and Pharmaceutical Press; 2018. p. 811.</p> <p>Taketomo, Carol K., J. H. Hodding, and D. M. Kraus. Pediatric and neonatal dosage handbook. Hudson (OH): Lexi Comp, 2010.</p> <p>Ainsworth SB. Neonatal formulary 7: drug use in pregnancy and the first year of life. Seventh ed. Chichester (West Sussex): John Wiley &amp; Sons Inc.; 2015. p247.</p> <p>Society of Hospital Pharmacists of Australia. Glycopyrronium Bromide. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2020 Feb 23]. Available from: <a href="http://aidh.hcn.com.au">http://aidh.hcn.com.au</a></p> <p>Truven Health Analytics. Glycopyrrolate. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2020 Feb 23 Available from: <a href="https://neofax.micromedexsolutions.com/">https://neofax.micromedexsolutions.com/</a></p>

Keywords:	Glycopyrrolate, glycopyrronium, respiratory secretions		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	January 2001	Version:	3.0
Last reviewed:	February 2020	Next review date:	February 2023
Endorsed by:	Neonatal Directorate Management Group	Date:	February 2020
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety		
<p><b>Printed or personally saved electronic copies of this document are considered uncontrolled.</b></p> <p><b>Access the current version from the WNHS website.</b></p> <p><b>For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a></b></p>			

© Department of Health Western Australia 2019